<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="CD004795.pub4" article-type="systematic-review" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cochrane Database Syst Rev</journal-id><journal-id journal-id-type="iso-abbrev">Cochrane Database Syst Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3102</journal-id><journal-id journal-id-type="pmc-domain">cochrev</journal-id><journal-id journal-id-type="publisher-id">14651858</journal-id><journal-title-group><journal-title>The Cochrane Database of Systematic Reviews</journal-title></journal-title-group><issn pub-type="epub">1469-493X</issn><issn-l>1361-6137</issn-l><publisher><publisher-name>John Wiley and Sons, Inc. and the Cochrane Library</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6532730</article-id><article-id pub-id-type="pmcid-ver">PMC6532730.1</article-id><article-id pub-id-type="pmcaid">6532730</article-id><article-id pub-id-type="pmcaiid">6532730</article-id><article-id pub-id-type="pmid">23744519</article-id><article-id pub-id-type="doi">10.1002/14651858.CD004795.pub4</article-id><article-id pub-id-type="publisher-id">CD004795.pub4</article-id><article-id pub-id-type="other">CD004795</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Tuberculosis</subject><subject>Child health</subject><subject>Infectious disease</subject><subject>Lungs &amp; airways</subject></subj-group></article-categories><title-group><article-title>Fluoroquinolones for treating tuberculosis (presumed drug&#8208;sensitive)</article-title></title-group><contrib-group><contrib id="d24e203" contrib-type="author" corresp="yes"><name name-style="western"><surname>Ziganshina</surname><given-names initials="LE">Lilia E</given-names></name><address><email>lezign@mail.ru</email><email>lezign@gmail.com</email></address><xref ref-type="aff" rid="CD004795-aff-0001"/></contrib><contrib id="d24e207" contrib-type="author"><name name-style="western"><surname>Titarenko</surname><given-names initials="AF">Albina F</given-names></name><xref ref-type="aff" rid="CD004795-aff-0001"/></contrib><contrib id="d24e211" contrib-type="author"><name name-style="western"><surname>Davies</surname><given-names initials="GR">Geraint R</given-names></name><xref ref-type="aff" rid="CD004795-aff-0002"/></contrib><contrib id="d24e222" contrib-type="editor"><collab collab-type="editors">Cochrane Infectious Diseases Group</collab></contrib></contrib-group><aff id="CD004795-aff-0001"><institution>Kazan (Volga region) Federal University</institution><institution content-type="dept">Department of Basic and Clinical Pharmacology</institution><addr-line>18 Kremlevskaya Street, 420008</addr-line><addr-line>14&#8208;15 Malaya Krasnaya Street, 420015</addr-line><city>Kazan</city><state>Tatarstan</state><country>Russian Federation</country></aff><aff id="CD004795-aff-0002"><institution>University of Liverpool</institution><institution content-type="dept">Institute of Infection and Global Health</institution><addr-line>Apex Building</addr-line><addr-line>8 West Derby Street</addr-line><city>Liverpool</city><state>Merseyside</state><country>UK</country><postal-code>L69 7BE</postal-code></aff><pub-date pub-type="epub"><day>6</day><month>6</month><year>2013</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2013</year></pub-date><pub-date pub-type="update"><day>30</day><month>5</month><year>2013</year></pub-date><volume>2013</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">332459</issue-id><elocation-id>CD004795</elocation-id><pub-history><event event-type="pmc-release"><date><day>06</day><month>06</month><year>2014</year></date></event><event event-type="pmc-live"><date><day>28</day><month>05</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-04 18:25:31.640"><day>04</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CD004795.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="updated-article" xml:lang="en" journal-id="Cochrane Database Syst Rev" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="18254061"><article-title>Fluoroquinolones for treating tuberculosis.</article-title><issue>1</issue><date><day>23</day><month>1</month><year>2008</year></date><fpage>CD004795</fpage><lpage>CD004795</lpage><source>Cochrane Database Syst Rev</source><pub-id pub-id-type="doi">10.1002/14651858.CD004795.pub3</pub-id><pub-id pub-id-type="pmid">18254061</pub-id></related-article><abstract><title>Abstract</title><sec id="CD004795-sec-0001"><title>Background</title><p>Currently the World Health Organization only recommend fluoroquinolones for people with presumed drug&#8208;sensitive tuberculosis (TB) who cannot take standard first&#8208;line drugs. However, use of fluoroquinolones could shorten the length of treatment and improve other outcomes in these people. This review summarises the effects of fluoroquinolones in first&#8208;line regimens in people with presumed drug&#8208;sensitive TB.</p></sec><sec id="CD004795-sec-0002"><title>Objectives</title><p>To assess fluoroquinolones as substitute or additional components in antituberculous drug regimens for drug&#8208;sensitive TB.</p></sec><sec id="CD004795-sec-0003"><title>Search methods</title><p>We searched the Cochrane Infectious Diseases Group Specialized Register; CENTRAL (<italic toggle="yes">The Cochrane Library</italic> 2013, Issue 1); MEDLINE; EMBASE; LILACS; Science Citation Index; Databases of Russian Publications; and <italic toggle="yes">meta</italic>Register of Controlled Trials up to 6 March 2013.</p></sec><sec id="CD004795-sec-0004"><title>Selection criteria</title><p>Randomized controlled trials (RCTs) of antituberculous regimens based on rifampicin and pyrazinamide and containing fluoroquinolones in people with presumed drug&#8208;sensitive pulmonary TB.</p></sec><sec id="CD004795-sec-0005"><title>Data collection and analysis</title><p>Two authors independently applied inclusion criteria, assessed the risk of bias in the trials, and extracted data. We used the risk ratio (RR) for dichotomous data and the fixed&#8208;effect model when it was appropriate to combine data and no heterogeneity was present. We assessed the quality of evidence using the GRADE approach.</p></sec><sec id="CD004795-sec-0006"><title>Main results</title><p>We identified five RCTs (1330 participants) that met the inclusion criteria. None of the included trials examined regimens of less than six months duration.</p><p><italic toggle="yes">Fluoroquinolones added to standard regimens</italic></p><p>A single trial (174 participants) added levofloxacin to the standard first&#8208;line regimen. Relapse and treatment failure were not reported. For death, sputum conversion, and adverse events we are uncertain if there is an effect (one trial, 174 participants, <italic toggle="yes">very low quality evidence for all three outcomes</italic>).</p><p><italic toggle="yes">Fluoroquinolones substituted for ethambutol in standard regimens</italic></p><p>Three trials (723 participants) substituted ethambutol with moxifloxacin, gatifloxacin, and ofloxacin into the standard first&#8208;line regimen. For relapse, we are uncertain if there is an effect (one trial, 170 participants, <italic toggle="yes">very low quality evidence</italic>). No trials reported on treatment failure. For death, sputum culture conversion at eight weeks, or serious adverse events we do not know if there was an effect (three trials, 723 participants, <italic toggle="yes">very low quality evidence for all three outcomes</italic>).</p><p><italic toggle="yes">Fluoroquinolones substituted for isoniazid in standard regimens</italic></p><p>A single trial (433 participants) substituted moxifloxacin for isoniazid. Treatment failure and relapse were not reported. For death, sputum culture conversion, or serious adverse events the substitution may have little or no difference (one trial, 433 participants, <italic toggle="yes">low quality evidence for all three outcomes</italic>).</p><p><italic toggle="yes">Fluoroquinolines in four month regimens</italic></p><p>Six trials are currently in progress testing shorter regimens with fluoroquinolones.</p></sec><sec id="CD004795-sec-0007"><title>Authors' conclusions</title><p>Ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin have been tested in RCTs of standard first&#8208;line regimens based on rifampicin and pyrazinamide for treating drug&#8208;sensitive TB. There is insufficient evidence to be clear whether addition or substitution of fluoroquinolones for ethambutol or isoniazid in the first&#8208;line regimen reduces death or relapse, or increases culture conversion at eight weeks. Much larger trials with fluoroquinolones in short course regimens of four months are currently in progress.</p></sec><sec id="CD004795-sec-0008"><p>6 June 2018</p><p>No update planned</p><p>Other</p><p>No update is currently planned; this is not currently a priority topic for update</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>Plain language summary</title><p><bold>Substituting or adding fluoroquinolones to established first&#8208;line antituberculous drug regimens gives no additional benefit or risks</bold></p><p>Tuberculosis is an infectious disease caused by <italic toggle="yes">Mycobacterium tuberculosis</italic> bacteria. Over two billion people worldwide are believed to be latently infected with TB and approximately 10% of these people will develop active TB later in life. The World Health Organization currently only recommend treatment with fluoroquinolones for patients who cannot take standard first&#8208;line drugs. In this review, we examined the effect of including fluoroquinolones in first&#8208;line treatment regimens on people with presumed drug&#8208;sensitive tuberculosis.</p><p>We examined the research published up to 6 March 2013 and we identified five randomised controlled trials (1330 people) that met the inclusion criteria. The trials were performed in low&#8208; and middle&#8208;income countries located in geographically diverse areas but there was a lack of studies conducted in Asia. We found no studies that examined the effect of including fluoroquinolones in a standard six month TB treatment regimen on treatment failure. We do not know whether adding fluoroquinolones or substituting fluoroquinolones for ethambutol in a standard six month TB treatment regimen reduces treatment failure, relapse, death, or adverse events. Substituting fluoroquinolones for isoniazid in a standard six month TB treatment regimen may have little or no difference upon death and adverse events. Currently, there are nine randomised controlled trials ongoing.</p><p>HIV&#8208;positive participants were relatively well&#8208;represented in the included trials but none of the included trials stratified outcomes by HIV status. Also, the primary outcomes of all the included trials were reached before initiation of antiretroviral treatment. Evidence is generally lacking on the safety and efficacy of fluoroquinolone additions or substitutions in children (&lt; 18 years) and in pregnant and lactating women.</p></abstract><kwd-group kwd-group-type="mesh"><kwd>Humans</kwd><kwd>Drug Substitution</kwd><kwd>Antitubercular Agents</kwd><kwd>Antitubercular Agents/therapeutic use</kwd><kwd>Ciprofloxacin</kwd><kwd>Ciprofloxacin/therapeutic use</kwd><kwd>Fluoroquinolones</kwd><kwd>Fluoroquinolones/therapeutic use</kwd><kwd>Levofloxacin</kwd><kwd>Ofloxacin</kwd><kwd>Ofloxacin/therapeutic use</kwd><kwd>Randomized Controlled Trials as Topic</kwd><kwd>Tuberculosis, Multidrug&#8208;Resistant</kwd><kwd>Tuberculosis, Multidrug&#8208;Resistant/drug therapy</kwd><kwd>Tuberculosis, Pulmonary</kwd><kwd>Tuberculosis, Pulmonary/drug therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="status-note"><p>Unchanged</p></notes></front></article></pmc-articleset>